77 related articles for article (PubMed ID: 20155475)
1. Novel D: -erythro N-octanoyl sphingosine analogs as chemo- and endocrine-resistant breast cancer therapeutics.
Antoon JW; Liu J; Ponnapakkam AP; Gestaut MM; Foroozesh M; Beckman BS
Cancer Chemother Pharmacol; 2010 May; 65(6):1191-5. PubMed ID: 20155475
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological activity of a family of novel ceramide analogues in chemoresistant breast cancer cells.
Antoon JW; Liu J; Gestaut MM; Burow ME; Beckman BS; Foroozesh M
J Med Chem; 2009 Sep; 52(18):5748-52. PubMed ID: 19694470
[TBL] [Abstract][Full Text] [Related]
3. Novel ceramide analogs as potential chemotherapeutic agents in breast cancer.
Struckhoff AP; Bittman R; Burow ME; Clejan S; Elliott S; Hammond T; Tang Y; Beckman BS
J Pharmacol Exp Ther; 2004 May; 309(2):523-32. PubMed ID: 14742741
[TBL] [Abstract][Full Text] [Related]
4. Novel anti-viability ceramide analogs: design, synthesis, and structure-activity relationship studies of substituted (S)-2-(benzylideneamino)-3-hydroxy-N-tetradecylpropanamides.
Liu J; Antoon JW; Ponnapakkam A; Beckman BS; Foroozesh M
Bioorg Med Chem; 2010 Jul; 18(14):5316-22. PubMed ID: 20639111
[TBL] [Abstract][Full Text] [Related]
5. Anti-proliferative effects of the novel ceramide analog (S)-2-(benzylideneamino)-3-hydroxy-N-tetrade-cylpropanamide in chemoresistant cancer.
Antoon JW; Beckman BS
Bioorg Med Chem Lett; 2012 Apr; 22(7):2624-8. PubMed ID: 22366655
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological activity of cell-penetrating peptide-modified octreotide analogs.
Xie W; Liu J; Qiu M; Yuan J; Xu A
J Pept Sci; 2010 Feb; 16(2):105-9. PubMed ID: 20014325
[TBL] [Abstract][Full Text] [Related]
7. Anticancer activity of a ceramide analog containing a disulfide linkage.
Bittman R; Li Z; Samadder P; Arthur G
Cancer Lett; 2007 Jun; 251(1):53-8. PubMed ID: 17141948
[TBL] [Abstract][Full Text] [Related]
8. The effect of quercetin on topotecan cytotoxicity in MCF-7 and MDA-MB 231 human breast cancer cells.
Akbas SH; Timur M; Ozben T
J Surg Res; 2005 May; 125(1):49-55. PubMed ID: 15836850
[TBL] [Abstract][Full Text] [Related]
9. Tailoring structure-function and targeting properties of ceramides by site-specific cationization.
Szulc ZM; Bielawski J; Gracz H; Gustilo M; Mayroo N; Hannun YA; Obeid LM; Bielawska A
Bioorg Med Chem; 2006 Nov; 14(21):7083-104. PubMed ID: 16919460
[TBL] [Abstract][Full Text] [Related]
10. Novel ceramide analogues display selective cytotoxicity in drug-resistant breast tumor cell lines compared to normal breast epithelial cells.
Crawford KW; Bittman R; Chun J; Byun HS; Bowen WD
Cell Mol Biol (Noisy-le-grand); 2003 Nov; 49(7):1017-23. PubMed ID: 14682383
[TBL] [Abstract][Full Text] [Related]
11. Bombesin analogs containing alpha-amino-isobutyric acid with potent anticancer activity.
Prasad S; Mathur A; Gupta N; Jaggi M; Singh AT; Rajendran P; Sanna VK; Datta K; Mukherjee R
J Pept Sci; 2007 Jan; 13(1):54-62. PubMed ID: 17031871
[TBL] [Abstract][Full Text] [Related]
12. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP
Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effects of curcumin and structurally beta-diketone modified analogs on multidrug resistant cancer cells.
Simoni D; Rizzi M; Rondanin R; Baruchello R; Marchetti P; Invidiata FP; Labbozzetta M; Poma P; Carina V; Notarbartolo M; Alaimo A; D'Alessandro N
Bioorg Med Chem Lett; 2008 Jan; 18(2):845-9. PubMed ID: 18039573
[TBL] [Abstract][Full Text] [Related]
14. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
15. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells.
Shuhendler AJ; Cheung RY; Manias J; Connor A; Rauth AM; Wu XY
Breast Cancer Res Treat; 2010 Jan; 119(2):255-69. PubMed ID: 19221875
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of human breast cancer metastasis in nude mice by synthetic glycoamines.
Glinsky GV; Price JE; Glinsky VV; Mossine VV; Kiriakova G; Metcalf JB
Cancer Res; 1996 Dec; 56(23):5319-24. PubMed ID: 8968076
[TBL] [Abstract][Full Text] [Related]
17. Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs.
Gewirtz DA; Di X; Walker TD; Sawyer ST
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2232-8. PubMed ID: 16609039
[TBL] [Abstract][Full Text] [Related]
18. 3-Ketone-4,6-diene ceramide analogs exclusively induce apoptosis in chemo-resistant cancer cells.
Ponnapakam AP; Liu J; Bhinge KN; Drew BA; Wang TL; Antoon JW; Nguyen TT; Dupart PS; Wang Y; Zhao M; Liu YY; Foroozesh M; Beckman BS
Bioorg Med Chem; 2014 Feb; 22(4):1412-20. PubMed ID: 24457089
[TBL] [Abstract][Full Text] [Related]
19. 19-nor-26,27-bishomo-vitamin D3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells.
Kubota T; Koshizuka K; Koike M; Uskokovic M; Miyoshi I; Koeffler HP
Cancer Res; 1998 Aug; 58(15):3370-5. PubMed ID: 9699668
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo anti-angiogenic activities and inhibition of hormone-dependent and -independent breast cancer cells by ceramide methylaminoethylphosphonate.
Chintalapati M; Truax R; Stout R; Portier R; Losso JN
J Agric Food Chem; 2009 Jun; 57(12):5201-10. PubMed ID: 19476359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
